Summary & Overview
HCPCS J1426: Injection, casimersen, 10 mg
HCPCS Level II code J1426 denotes the injectable medication casimersen, billed per 10 mg unit. As a specialty injectable, casimersen is administered in outpatient clinical settings — including hospital outpatient departments, physician offices, and specialty infusion centers — and is relevant for payers and providers managing high-cost, provider-administered therapies. Nationally, accurate use of J1426 affects claims processing, benefit design, and specialty drug spend tracking.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing and coding context for J1426, common payer considerations, and the types of benchmarks and policy updates typically relevant for HCPCS-level specialty drug codes. The publication outlines clinical context for an injectable biologic, expected sites of service, and payer coverage themes that influence medical necessity review, prior authorization patterns, and reimbursement workflows.
This summary equips billing managers, revenue cycle staff, and policy analysts with the essential framing needed to interpret provider and payer interactions around HCPCS Level II code J1426 and to locate more detailed benchmarks, coverage policy language, and clinical guidance where available.
Billing Code Overview
HCPCS Level II code J1426 describes Injection, casimersen, 10 mg. This code represents a physician-administered or outpatient injectable medication formulation of casimersen, billed per 10 mg unit. The service type is an injectable biologic/specialty medication used in clinical settings where infused or injected therapies are administered. The typical site of service is hospital outpatient departments, physician offices, or specialty infusion/administration centers where parenteral medications are given.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adolescent or adult with Duchenne muscular dystrophy (DMD) who is eligible for targeted exon-skipping therapy with casimersen. The patient presents to an outpatient infusion or specialty injection clinic for administration of J1426 (injection, casimersen, 10 mg). Prior to the visit, the patient’s prescription is verified against the medical record confirming the dystrophin gene mutation amenable to exon 45 skipping. Baseline vitals, height/weight for dose calculation, and recent laboratory tests (liver function tests, renal panel) are reviewed. The medication is prepared by pharmacy and delivered to the clinic in a nursing area certified for specialty biologic handling. A registered nurse performs pre-injection assessment, verifies site of service, confirms informed consent and allergies, and documents any prior adverse reactions to antisense oligonucleotide therapies. The nurse administers the intravenous or subcutaneous injection per manufacturer guidance (site, rate), observes the patient for acute infusion-related or hypersensitivity reactions for a monitored recovery period, and documents lot number, dose, and administration route in the medical record. If an adverse event occurs, the clinic applies appropriate emergency measures and documents the event. Follow-up scheduling is arranged for ongoing regular dosing and laboratory monitoring as specified in the prescribing information.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier |